Andy Minn

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10058166/publications.pdf

Version: 2024-02-01

50	20,487	87888 38	206112 48
papers	citations	h-index	g-index

51	51	51	30410
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Abstract 3444: Administration of anti-CD40 enhances local and systemic antitumor efficacy of radiotherapy in allograft tumor model of a check-point blockade resistant melanoma. Cancer Research, 2022, 82, 3444-3444.	0.9	0
2	Abstract IA-019: Preclinical studies with proton FLASH radiotherapy in mice and canines: Biological effects, biophysical considerations and potential mechanisms. , 2021, , .		0
3	FLASH Proton Radiotherapy Spares Normal Epithelial and Mesenchymal Tissues While Preserving Sarcoma Response. Cancer Research, 2021, 81, 4808-4821.	0.9	77
4	A stratified phase I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes. OncoImmunology, 2021, 10, 1863631.	4.6	16
5	Combining Radiation with Immunotherapy: The University of Pennsylvania Experience. Seminars in Radiation Oncology, 2020, 30, 173-180.	2.2	6
6	DENDRO: genetic heterogeneity profiling and subclone detection by single-cell RNA sequencing. Genome Biology, 2020, 21, 10.	8.8	35
7	Design, Implementation, and inÂVivo Validation of a Novel Proton FLASH Radiation Therapy System. International Journal of Radiation Oncology Biology Physics, 2020, 106, 440-448.	0.8	274
8	p27 transcriptionally coregulates cJun to drive programs of tumor progression. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7005-7014.	7.1	29
9	Survivorship care planning in skin cancer: An unbiased statistical approach to identifying patterns of careâ€plan use. Cancer, 2018, 124, 183-191.	4.1	7
10	Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies. Immunity, 2018, 48, 417-433.	14.3	416
11	A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. British Journal of Cancer, 2018, 119, 1200-1207.	6.4	83
12	Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer. Cancer Research, 2018, 78, 4282-4291.	0.9	83
13	Radiation and Immune Checkpoint Blockade: From Bench to Clinic. Seminars in Radiation Oncology, 2017, 27, 289-298.	2.2	39
14	Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature, 2017, 548, 466-470.	27.8	1,042
15	Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling. Cell, 2016, 165, 272-275.	28.9	224
16	Assessing intratumor heterogeneity and tracking longitudinal and spatial clonal evolutionary history by next-generation sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E5528-37.	7.1	200
17	Getting Tumor Dendritic Cells to Engage the Dead. Cancer Cell, 2015, 28, 685-687.	16.8	1
18	Awakening the immune system with radiation: Optimal dose and fractionation. Cancer Letters, 2015, 368, 185-190.	7.2	91

#	Article	IF	Citations
19	Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature, 2015, 520, 373-377.	27.8	1,955
20	Tumour exosome integrins determine organotropic metastasis. Nature, 2015, 527, 329-335.	27.8	3,688
21	MicroRNA-124 expression counteracts pro-survival stress responses in glioblastoma. Oncogene, 2015, 34, 2204-2214.	5.9	51
22	miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 291-296.	7.1	101
23	Exosome Transfer from Stromal to Breast Cancer Cells Regulates Therapy Resistance Pathways. Cell, 2014, 159, 499-513.	28.9	659
24	Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in Î³â€secretase inhibitor drug responses. EMBO Molecular Medicine, 2013, 5, 1502-1522.	6.9	62
25	Targeting of TGFÂ signature and its essential component CTGF by miR-18 correlates with improved survival in glioblastoma. Rna, 2013, 19, 177-190.	3.5	45
26	TAp73 enhances the pentose phosphate pathway and supports cell proliferation. Nature Cell Biology, 2013, 15, 991-1000.	10.3	198
27	PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. Breast Cancer Research and Treatment, 2013, 138, 369-381.	2.5	46
28	Identification of novel metastasis suppressor signaling pathways for breast cancer. Cell Cycle, 2012, 11, 2452-2457.	2.6	25
29	Signalling pathway for RKIP and Let-7 regulates and predicts metastatic breast cancer. EMBO Journal, 2011, 30, 4500-4514.	7.8	175
30	High-Dimensional Variable Selection for Survival Data. Journal of the American Statistical Association, 2010, 105, 205-217.	3.1	329
31	Multimodality imaging of TGFÎ² signaling in breast cancer metastases. FASEB Journal, 2009, 23, 2662-2672.	0.5	50
32	Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. EMBO Journal, 2009, 28, 347-358.	7.8	340
33	Genes that mediate breast cancer metastasis to the brain. Nature, 2009, 459, 1005-1009.	27.8	1,587
34	An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 18490-18495.	7.1	484
35	Lung metastasis genes couple breast tumor size and metastatic spread. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 6740-6745.	7.1	331
36	Signal Transducer and Activator of Transcription 1 Regulates Both Cytotoxic and Prosurvival Functions in Tumor Cells. Cancer Research, 2007, 67, 9214-9220.	0.9	119

#	Article	IF	Citations
37	RAD51 Up-regulation Bypasses BRCA1 Function and Is a Common Feature of BRCA1-Deficient Breast Tumors. Cancer Research, 2007, 67, 9658-9665.	0.9	156
38	Identifying Site-specific Metastasis Genes and Functions. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 149-158.	1.1	91
39	Genes that mediate breast cancer metastasis to lung. Nature, 2005, 436, 518-524.	27.8	2,581
40	Cyclin-dependent Kinase Inhibitors Uncouple Cell Cycle Progression from Mitochondrial Apoptotic Functions in DNA-damaged Cancer Cells. Journal of Biological Chemistry, 2005, 280, 32018-32025.	3.4	36
41	Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. Journal of Clinical Investigation, 2005, 115, 44-55.	8.2	606
42	Bcl-xL regulates apoptosis by heterodimerization-dependent and -independent mechanisms. EMBO Journal, 1999, 18, 632-643.	7.8	184
43	Bcl-xL forms an ion channel in synthetic lipid membranes. Nature, 1997, 385, 353-357.	27.8	810
44	Identification of a novel regulatory domain in Bcl-xL and Bcl-2. EMBO Journal, 1997, 16, 968-977.	7.8	266
45	Structure of Bcl-xL-Bak Peptide Complex: Recognition Between Regulators of Apoptosis. Science, 1997, 275, 983-986.	12.6	1,394
46	Chapter 15 Designer antibodies. Principles of Medical Biology, 1996, , 281-302.	0.1	4
47	Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage.. Genes and Development, 1996, 10, 2621-2631.	5.9	226
48	Growth factors can enhance lymphocyte survival without committing the cell to undergo cell division.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 5491-5495.	7.1	142
49	CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL. Immunity, 1995, 3, 87-98.	14.3	1,099
50	Receptors That Regulate T-Cell Susceptibility to Apoptotic Cell Death. Annals of the New York Academy of Sciences, 1995, 766, 70-80.	3.8	21